OncoSec Medical Poised for Exciting 2014
Investors looking for an interesting opportunity in biotechnology may want to consider OncoSec Medical (ONCS.PK). Shares of OncoSec Medical have exploded by 40 percent over the past month as investors try to grab shares before things start to heat up in 2014.
OncoSec Medical is a development-stage biotechnology company that is developing treatments for advanced-stage skin cancer. The company focuses on three types of skin cancer: melanoma, cutaneous T-cell lymphoma, and Merkel cell lymphoma. The company’s platform revolves around the theory of immunotherapy. The basic idea of immunotherapy is to embrace the power of using a person’s immune system to help eradicate a disease.
I would argue that immunotherapy has been the theme of 2013, as several companies have seen enormous gains because of its potential. One such company is Celldex Therapeutics (NASDAQ:CLDX). Shares of Celldex are up about 250 percent over the past 52 weeks. Celldex has shown great promise with its deep pipeline, including a couple of candidates that have the potential to offer breakthrough treatments for breast and brain cancer, among others.
Immunotherapy is also catching the attention of major banks such as Citigroup. Citigroup research analyst Andrew Baum expects immunotherapies to make up the majority of treatments for up to 60 percent of cancers over the next 10 years. Currently, immunotherapies only comprise 3 percent of cancer treatments. Baum expects that the rise in immunotherapy use will create an annual market size of $35 billion. With that potential, it is hard not to like a company like OncoSec Medical, currently valued at just $75 million.